Lesson
Map the Infection Before Naming the Regimen
Cervicitis is lower-tract inflammation. PID is an ascending upper-tract syndrome that can involve the endometrium, fallopian tubes, ovaries, pelvic peritoneum, or a tubo-ovarian abscess. The distinction changes urgency, antimicrobial breadth, duration, and follow-up.
- Cervix
- Endometrium
- Fallopian tube
- Polymicrobial ascent
- Tubal injury
- Reproductive sequelae
Exudate, friability, bleeding, and organism testing
Upper-tract inflammation may outlast a cervical signal
Gonorrhea, chlamydia, anaerobes, and vaginal flora
Early therapy limits scarring and reproductive sequelae
Separate lower from upper tract
Cervicitis produces mucopurulent endocervical discharge or cervical friability and may cause intermenstrual or postcoital bleeding. PID adds pelvic or lower abdominal pain and upper-tract tenderness, with or without fever or systemic illness.
Understand ascent
Gonorrhea and chlamydia are important initiators, but anaerobes, BV-associated flora, and other organisms contribute. PID therapy therefore covers a polymicrobial syndrome rather than only the organism detected at the cervix.
Respect imperfect concordance
A negative endocervical gonorrhea or chlamydia NAAT does not rule out upper-tract infection. Organisms may no longer be detectable below, and non-gonococcal, non-chlamydial pathogens can participate.
Connect inflammation to structure
Endosalpinx inflammation can scar or obstruct the fallopian tube. The resulting infertility, ectopic pregnancy, chronic pelvic pain, or recurrent PID can remain after acute symptoms and organisms resolve.
Treat time as a clinical variable
No single test proves or excludes every PID case. When the clinical threshold is met, early empiric treatment protects against the cost of waiting for certainty while the differential continues in parallel.
Quick check
Lesson
Recognize Cervicitis and Protect the Upper-Tract Pathway
Cervicitis can be asymptomatic, present as abnormal discharge or bleeding, and coexist with PID. Objective cervical inflammation starts the workup, but every assessment must also ask whether infection has moved above the cervix.
- Mucopus
- Friability
- Bleeding
- NAAT
- Vaginitis overlap
- PID screen
Document an objective cervical phenotype
Friability is one of the two major signs
Use NAAT and acknowledge microscopy limits
Pelvic pain and upper-tract tenderness change the pathway
Find the two major signs
Mucopurulent endocervical exudate and sustained endocervical bleeding induced by gentle swab passage are the major diagnostic signs. Either can be present without the other.
Build the organism differential
Chlamydia and gonorrhea are common identified causes. Trichomoniasis, primary genital herpes, and M. genitalium are associated causes. Many cases have no organism identified, especially in lower-risk adults.
Avoid low-value testing
Routine testing for Ureaplasma species, Mycoplasma hominis, or group B streptococcal genital culture is not recommended for cervicitis. These results can distract from validated pathways.
Assess overlapping vaginitis
Evaluate for BV and trichomoniasis. A negative wet mount does not exclude trichomoniasis in a symptomatic patient because microscopy has limited sensitivity, so use a more sensitive validated test when suspicion remains.
Screen every case for PID
Ask about pelvic pain, fever, dyspareunia, and abnormal bleeding. Assess pregnancy and upper-tract tenderness when appropriate. Cervicitis can be the visible edge of endometritis or salpingitis.
Quick check
Lesson
Test, Treat, and Close Cervicitis Deliberately
The treatment decision depends on organism risk, gonorrhea prevalence, NAAT access, pregnancy, and confidence that results and follow-up will reach the patient. Presumptive treatment is a structured risk decision, not a reflex.
- Risk
- NAAT
- Doxycycline
- Gonorrhea coverage
- Partner care
- Retesting
Age, exposure, prevalence, test access, and return reliability
Add gonorrhea coverage when risk or prevalence warrants
Treat detected infections and confirm inflammation clears
Address the prior 60 days and three-month reinfection risk
Use appropriate NAAT
Test for chlamydia and gonorrhea with a validated vaginal, cervical, or urine NAAT. Test for HIV and syphilis, and address BV or trichomoniasis when detected.
Decide whether to treat now
Provide presumptive chlamydia and gonorrhea therapy when risk is increased, NAAT is unavailable, or follow-up is uncertain. For lower-risk patients with reliable follow-up, deferring therapy until results return is an option.
Use the cervicitis regimen
CDC recommends doxycycline 100 mg orally twice daily for seven days. Azithromycin 1 g once is an alternative. Add concurrent gonorrhea treatment when the patient is at risk or local prevalence is high, and use pregnancy-specific pathogen guidance when pregnant.
Close transmission pathways
Patients treated for cervicitis should avoid sex until they and their partners are treated, the seven-day regimen is complete or seven days have passed after single-dose therapy, and symptoms have resolved.
Follow results and recurrence
Verify resolution and communicate results. When chlamydia, gonorrhea, or trichomoniasis is identified, manage partners from the previous 60 days and repeat testing at three months because reinfection is common.
Quick check
Lesson
Diagnose PID with a Deliberately Sensitive Threshold
PID is a clinical diagnosis built under uncertainty. In an at-risk patient with pelvic or lower abdominal pain and no better cause, one or more minimum pelvic tenderness criteria can justify presumptive treatment while urgent alternatives remain under evaluation.
- Pelvic pain
- Cervical motion tenderness
- Uterine tenderness
- Adnexal tenderness
- Supportive evidence
- Differential
No better cause identified
Cervical motion, uterine, or adnexal tenderness
Fever, leukocytes, inflammation, discharge, or NAAT
Pregnancy, torsion, appendicitis, ectopic pregnancy, and abscess
Use the minimum criteria
Cervical motion tenderness, uterine tenderness, or adnexal tenderness can meet the minimum examination threshold in the appropriate clinical setting. Requiring all three findings reduces sensitivity.
Add specificity
Fever, mucopurulent discharge, cervical friability, abundant vaginal leukocytes, elevated inflammatory markers, or documented gonorrhea or chlamydia increase specificity but are not universally required.
Test without delaying therapy
Obtain a pregnancy test and test for gonorrhea, chlamydia, HIV, and syphilis. Consider imaging when abscess, mass, torsion, ectopic pregnancy, appendicitis, or another alternate diagnosis is possible.
Interpret microscopy
If cervical discharge is normal and vaginal fluid lacks leukocytes, PID becomes less likely and another cause deserves attention. These findings adjust probability but do not replace the whole examination.
Keep emergencies active
Hemodynamic instability, peritoneal signs, focal severe pain, pregnancy, atypical progression, or absent response require urgent reassessment for surgical and obstetric causes even after empiric antibiotics begin.
Quick check
Lesson
Decide Who Needs Hospital Care
Mild-to-moderate PID can often be treated outside the hospital, but severity, pregnancy, abscess, diagnostic uncertainty, oral intolerance, treatment reliability, and response determine disposition.
- Pregnancy
- Surgical emergency
- Abscess
- Severe illness
- Oral tolerance
- 72-hour response
Escalate the complicated phenotype
Do not let infection hide another urgent cause
Route must match what the patient can absorb and complete
Nonresponse demands hospitalization and diagnostic reset
Hospitalize for danger or uncertainty
Hospital care is appropriate when a surgical emergency cannot be excluded, tubo-ovarian abscess is present, pregnancy exists, illness is severe, nausea or vomiting prevents oral therapy, or fever exceeds 38.5 C.
Hospitalize when outpatient care cannot work
An inability to follow or tolerate the outpatient regimen and failure to respond to oral therapy are independent reasons to escalate. Treatment access and reliability are clinical facts.
Use the same evidence in adolescents
Adolescents do not have better outcomes from hospitalization solely because of age. Apply the same severity and feasibility criteria while protecting confidentiality, access, and safeguarding needs.
Treat abscess as complicated disease
Tubo-ovarian abscess requires inpatient observation beyond 24 hours, effective anaerobic coverage, serial response assessment, and possible drainage or surgery when rupture, sepsis, size, or nonresponse demands source control.
Make 72 hours nonnegotiable
Outpatient disease should improve within 72 hours. Persistent fever or tenderness requires hospitalization, regimen and adherence review, additional diagnostics, and reconsideration of the diagnosis.
Quick check
Lesson
Deliver Complete Outpatient PID Therapy
The outpatient regimen is a coordinated three-drug system. Ceftriaxone covers gonorrhea, doxycycline covers chlamydia and other susceptible organisms, and metronidazole extends anaerobic and BV-associated coverage.
- Ceftriaxone
- Doxycycline
- Metronidazole
- 14 days
- Administration
- Follow-up
Gonococcal coverage begins immediately
Chlamydial and susceptible organism coverage
Anaerobic and concurrent BV coverage
Improvement must be evident within 72 hours
Use the recommended regimen
Give ceftriaxone 500 mg IM once plus doxycycline 100 mg orally twice daily for 14 days with metronidazole 500 mg orally twice daily for 14 days for mild-to-moderate acute PID.
Check the weight qualifier
For a patient weighing at least 150 kg with documented gonococcal infection, use ceftriaxone 1 g. Confirm both the measured weight and organism context before applying the adjustment.
Preserve anaerobic coverage
Metronidazole improves eradication of anaerobes from the upper genital tract and also treats frequently concurrent BV. Removing it without rebuilding anaerobic coverage creates an incomplete regimen.
Teach doxycycline administration
Use water, remain upright, avoid taking immediately before bed, separate from interacting polyvalent cations when appropriate, manage photosensitivity risk, and complete 14 days even after early symptom improvement.
Engineer adherence
Confirm both oral medicines can be obtained, tolerated, stored, and completed. Counsel about adverse effects, interactions, candidiasis, temporary abstinence, and return within 72 hours or sooner for worsening disease.
Quick check
Lesson
Escalate, Transition, and Complete Inpatient Therapy
Parenteral therapy is selected for severity, abscess, pregnancy, oral intolerance, uncertainty, or outpatient failure. Improvement usually permits a transition within 24 to 48 hours, but total therapy remains 14 days.
- Ceftriaxone IV
- Doxycycline
- Metronidazole
- Alternative regimens
- Oral transition
- Total duration
Ceftriaxone, doxycycline, and metronidazole
Follow fever, tenderness, abscess, and alternate diagnoses
Move after 24 to 48 hours of improvement
Discharge changes route, not the therapeutic objective
Use a recommended parenteral regimen
One recommended regimen is ceftriaxone 1 g IV every 24 hours plus doxycycline 100 mg every 12 hours plus metronidazole 500 mg every 12 hours.
Use oral bioavailability intelligently
Doxycycline and metronidazole have strong oral bioavailability. Oral dosing can be used when tolerated, and oral doxycycline avoids painful IV infusion. Route should match clinical physiology.
Transition after improvement
After 24 to 48 hours of clinical improvement, transition to oral doxycycline 100 mg twice daily and metronidazole 500 mg twice daily to complete 14 total days.
Know the alternatives
Cefotetan plus doxycycline or cefoxitin plus doxycycline are recommended options. Ampicillin-sulbactam plus doxycycline and clindamycin plus gentamicin are alternative pathways with different allergy, toxicity, and abscess considerations.
Protect abscess coverage
When tubo-ovarian abscess is present after clindamycin and gentamicin, complete therapy with doxycycline plus clindamycin or metronidazole so anaerobic coverage is preserved.
Quick check
Lesson
Reset the Differential When Inflammation Persists
Persistent cervicitis or PID requires a fresh assessment of adherence, re-exposure, partners, common pathogens, anatomy, and noninfectious disease. M. genitalium matters, but it is not permission for universal moxifloxacin.
- Re-exposure
- NAAT
- Macrolide resistance
- Moxifloxacin
- Evidence limits
- Noninfectious causes
Confirm partner care, completion, and organism results
Use selected testing and resistance guidance
Avoid efficient selection of macrolide resistance
Polyps, dysplasia, irritants, and idiopathic inflammation remain
Reassess before retreating
Confirm the prior regimen, completion, vomiting, partner treatment, interval sex, organism results, BV, trichomoniasis, and whether the current symptoms still localize to the cervix or upper tract.
Test selected persistent disease
Women with recurrent cervicitis should receive an FDA-cleared M. genitalium NAAT, ideally with resistance testing when available. Testing can be considered in PID, especially persistent disease.
Do not use single-dose azithromycin
M. genitalium lacks a cell wall and has high macrolide resistance. Azithromycin 1 g alone can select resistance and should not be used as treatment for this organism.
Respect the PID evidence boundary
Standard PID regimens are not reliably effective against M. genitalium. If it is detected in PID, moxifloxacin 400 mg daily for 14 days has been used, but the benefit of routine testing and directed therapy remains uncertain.
Refer noninfectious persistence
When reinfection and relevant infections are excluded, evaluate dysplasia, polyps, irritants, altered flora, or idiopathic inflammation. Repeated prolonged antibiotics have undefined value and can delay the actual diagnosis.
Quick check
Lesson
Adapt the Plan Without Losing the Syndrome
Pregnancy, IUD use, HIV, adolescence, allergy, and abscess change disposition, monitoring, or drug selection. They do not erase the core need for early broad treatment and measured response.
- Pregnancy
- IUD
- Adolescence
- HIV
- Allergy
- Abscess
Hospital, IV therapy, and specialist consultation
Treat first and reassess before considering removal
Use severity rather than demographic reflexes
Characterize the reaction before abandoning ceftriaxone
Escalate pregnancy
Suspected PID in pregnancy requires hospitalization, IV antimicrobials, and infectious disease plus obstetric consultation because maternal morbidity and preterm delivery risk are increased.
Manage an IUD by response
An IUD does not require immediate removal when PID is diagnosed. Treat and follow closely. Consider removal if there is no improvement within 48 to 72 hours, using patient preference and contraceptive needs.
Avoid age-based reflexes
Adolescents use the same hospitalization criteria as adults. Address confidentiality, safeguarding, adherence, cost, transportation, and partner access without turning age alone into a severity marker.
Treat HIV with the recommended regimens
Patients with HIV generally respond to recommended outpatient or parenteral regimens similarly. Evaluate severity and tubo-ovarian abscess, which can be more frequent, rather than escalating every case by HIV status alone.
Interrogate allergy precisely
Cross-reactivity with third-generation cephalosporins such as ceftriaxone is negligible for most penicillin-allergy histories. Clarify the reaction, timing, and severity before abandoning the preferred coverage.
Quick check
Lesson
Close the Patient, Partner, and Reproductive Loops
Microbiologic treatment is only one layer of success. Clinical improvement, partner therapy, temporary abstinence, STI testing, retesting, recurrence prevention, and reproductive follow-up complete the care system.
- Clinical response
- Partners
- Abstinence
- Retesting
- Sequelae
- Prevention
Fever and tenderness improve within 72 hours
Reach contacts from the preceding 60 days
Detect reinfection after gonococcal or chlamydial PID
Address pain, recurrence, fertility, and ectopic risk
Measure improvement
Within 72 hours, fever and direct or rebound abdominal, uterine, adnexal, and cervical motion tenderness should improve. Worsening or nonresponse triggers hospitalization and diagnostic reassessment.
Treat exposed partners
Partners with sexual contact during the 60 days before symptom onset should be evaluated, tested, and presumptively treated for chlamydia and gonorrhea. If the last contact was earlier, treat the most recent partner.
Define temporary abstinence
Avoid sex until the complete patient regimen is finished, symptoms have resolved, and partners have been treated. Use neutral language and assess privacy, coercion, and safety.
Retest on the correct timeline
For chlamydial or gonococcal PID, repeat testing at three months regardless of reported partner treatment. If that is impossible, retest at the next medical encounter within 12 months.
Follow long-term outcomes
Recurrent pain, infertility concerns, ectopic pregnancy risk, or recurrent symptoms need gynecologic and reproductive follow-up. Prevention includes barrier counseling, screening, rapid treatment, and accessible partner services.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 132 question bank.
Each attempt draws a fresh set and rearranges the answer choices.